Objectives: To evaluate associations of DNA methylation of the human tumour suppressor gene EPB41L3 with high-grade cervical intraepithelial neoplasia (CIN2þ) and HIV-related factors among women living with HIV-1 (WLHIV) in Burkina Faso and South Africa.
Introduction
Invasive cervical cancer (ICC) is one of the most common cancers in low and middle-income countries (LMIC), where 85% of the estimated 500 000 global annual cases occur [1] , and it is the leading cause of cancer deaths among African women [2] . ICC incidence and mortality remain high in LMIC, as organized screening and HPV vaccination programmes are limited. In sub-Saharan Africa, the prevalence of both ICC and HIV is high [3, 4] . Women living with HIV (WLHIV) are living longer because of increased availability of antiretroviral therapy (ART) and many retain a high risk of infection with HPVand high risk of progressing to cervical and other genital cancers [5, 6] .
The performance of currently available screening tests for high-grade cervical intraepithelial neoplasia grade 2 or greater (CIN2þ) or worse among WLHIV is not optimal. Cervical cytology and visual inspection using acetic acid (VIA) or Lugol's iodine (VILI) are more frequently used in Sub-Saharan Africa, but also have poor accuracy and reproducibility [7] [8] [9] . HPV DNA-based screening has high sensitivity for CIN2þ, but as it detects many transient infections, it has low specificity [10] . This has important implications for screening WLHIV among whom the prevalence of high-risk HPV is high [11] . Novel methods are required that are sensitive enough to detect clinically relevant high-risk HPV needing colposcopy referral and treatment but with high specificity to rule out HPV-positive women without evidence of disease, thereby avoiding the need for repeat testing, which can result in substantial losses to follow-up [12, 13] , and unnecessary referrals for colposcopy, which increase costs and burden to the service.
Although high-risk HPV is necessary for the development of CIN2þ [14] , other molecular changes occur during high-risk HPV infection that lead to alterations in the functions of gene products regulating tumour suppression and cell cycle progression. Some precancerous tissue changes are the result of DNA methylation of human genes and HPV virus [15] . Aberrant DNA methylation is a potentially good early indicator of underlying disease and may help distinguish nonprogressive HPV infections from those that will progress to cancer [16] . A combined panel of human tumour suppressor gene DNA methylation markers CADM1, MAL and MiR has shown good performance for CIN2þ detection among WLHIV in Kenya [17] and South Africa [18] . DNA methylation of another human tumour suppressor gene EPB41L3, alone or combined with HPV16/18/31/33, has shown good performance for CIN2þ detection in the general population of women in the UK [19] , the Netherlands [20] and Canada [21] . However, there are no studies evaluating this marker among WLHIV to date.
We conducted a prospective study of cervical cancer screening in a cohort of WLHIV in Burkina Faso and South Africa [6] . In this article, we sought to evaluate associations of EPB41L3 DNA methylation with prevalent, incident and persistent CIN2/3; and with HIV-related factors such as CD4 þ cell count and antiretroviral therapy (ART) use, and to evaluate the performance of EPB41L3 DNA methylation testing for the detection of prevalent CIN2þ.
Materials and methods

Study population
We used DNA isolated from stored cervical swabs collected as part of an evaluation study of cervical cancer screening strategies in Ouagadougou (Burkina Faso), and Johannesburg (South Africa), as previously described [6] . In brief, women were included in the HARP (HPV in Africa Research Partnership) study if they were HIV-1 seropositive, aged 25-50 years and resident of the study city; and excluded if they had a history of prior treatment for cervical cancer, previous hysterectomy, or were pregnant or less than 8 weeks postpartum. Enrolment was stratified in a 2 : 1 ratio of ART-users: ART-naïve WLHIV. Participants were followed-up every 6 months for CD4
þ T-lymphocyte cell count and up to month 18 whenever procedures similar to baseline were repeated.
As part of this nested case-control study, all cases of histologically confirmed CIN2þ detected at baseline (prevalent) with sufficient cervical DNA [Burkina Faso: 87.5% (28/32); South Africa: 96.1% (124/129)] were included and matched with at least one control without CIN (CIN1) by age group (<35 years and 35 years) and country of recruitment (Burkina Faso: 66; South Africa: 144; Fig. 1 ). Given the low numbers of CIN2þ cases in Burkina Faso, more than one age-matched control were recruited from this site. High-risk HPV infection was not considered as part of the matching criteria given the high prevalence in this population (59% in Burkina Faso and 79% in South Africa) [6] .
High-risk HPV genotyping and the EPB41L3 DNA methylation assay Cervical samples were collected using a Digene cervical sampler (Qiagen, Courtaboeuf, France) for high-risk HPV DNA testing and genotyping and DNA methylation assays. High-risk HPV testing was performed at baseline and endline at the University of Montpellier virology laboratory using genotyping with the INNOLiPA HPV genotyping Extra assay (Innogenetics, Courtaboeuf, France) [22] . The EPB41L3 methylation assays (CpG sites: 438, 427 and 425) were performed at baseline and endline using DNA isolation, bisulphite conversion and quantification of methylation using pyrosequencing (PSQ) assays in single separate reactions, as previously described [23] . Primers were designed using PyroMark Assay Design software version 2.0.1.15 (Qiagen; Supplementary Table 1, http://links.lww.com/ QAD/B325). A non-CpG cytosine was included to provide the internal control for total bisulfphite conversion by the PSQ assay. PCR assays were performed as previously described [24] . All runs included standard curves as positive controls, of 0, 50 and 100% methylated human DNA and a nonmethylated control.
Visual inspection, cytology and histology An additional cervical brush was collected from the ectocervix and endocervix for cytological reading using the Papanicolaou method and read at the Pathology department at CHU-Yalgado in Ouagadougou and the National Health Laboratory Service (NHLS), Johannesburg according to the Bethesda classification system [25] . All participants were assessed clinically using visual inspection with acetic acid or Lugol's iodine (VIA/ VILI) by trained nurses/midwives. All participants were referred for colposcopy performed by trained colposcopists. Systematic four-quadrant cervical biopsy, including directed biopsy of any suspicious lesions, was performed for participants who had abnormalities detected by cytology, VIA/VILI or colposcopy, or who were high-risk HPV DNA positive using Digene HC-II (Qiagen).
Cervical biopsies were processed at the local pathology laboratories and read using the three-tier CIN classification system [26] . Histology was classified as 'negative' (CIN1) or 'positive' (CIN2þ) based on the highest reading across all findings from the four-quadrant biopsies and endocervical curettage if collected. All histological slides from women with a local diagnosis of CIN2þ and approximately 10% of slides from women with CIN1 histological findings were reviewed by the HARP Endpoint Committee of five pathologists, for consensus classification, which showed high agreement [27] .
The same genital sampling and examination procedures were repeated at the endline visit.
Statistical analyses
The three CpG sites for EPB41L3 were highly correlated (Supplementary Table 2 , http://links.lww.com/QAD/ B325) justifying the use of the average of the three CpG sites. The median methylation values of the average of the CpG sites for EPB41L3 were compared across histological grades using the nonparametric Mann-Whitney U test [28] as values were not normally distributed. The Cuzick test for trend was used to evaluate trend in methylation levels by CIN grade [29] . Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
EPB41L3 methylation values were dichotomized into 'high' and 'low' methylation levels, with 'high' defined as values above the second tertile (66.7 percentile point) of the distribution of values in the control (CIN1) samples, as previously used [30] and this cut-off was country-specific. Logistic regression was used, combining cases and controls, to obtain odds ratios (OR) and 95% confidence intervals (CI) for 'high' methylation associated with sociodemographic, behavioural and HIV-related factors [31] . Multivariable analyses were adjusted for factors, which were independently associated with 'high' methylation in univariate analyses (P < 0.10) for each country.
Receiver operating characteristic (ROC) curves were plotted for the outcome of CIN2þ. The area under the ROC curve (AUC) was used to evaluate the sensitivity and specificity of the EPB41L3 methylation assay for the detection of CIN2þ and CIN3þ. McNemar's test was used to compare the sensitivity and specificity of the EPB41L3 methylation assay with current standard-ofscreening in Burkina Faso (visual inspection) and South Africa (cytology) [32] . Data were analysed using Stata version 14 (Stata Statistical Software, College Station. Texas, USA: Stata Corporation).
Ethics
Ethical approval for the HARP study was granted from the Ministry of Health in Burkina Faso, the University of Witwatersrand in South Africa, and the London School of Hygiene and Tropical Medicine in the UK.
Results
Study population
A full description of the HARP Study cohort (Burkina Faso: 615; South Africa: 623) is provided elsewhere [6] . For this study, the median age of 94 participants in Burkina Faso (28 CIN2þ cases, 66 CIN1 controls) was 39 (IQR 35-43) years and 33 (IQR: 30-38) among 268 participants in South Africa (124 CIN2þ cases, 144 CIN1 controls), similar to the overall HARP cohort. The median CD4 þ count at baseline was 453 cell/ml (IQR: 303-594) in Burkina Faso and 403 cell/ml (IQR: 283-551) in South Africa, similar to the HARP cohort. There was a higher proportion of women taking ART in Burkina Faso compared with those in South Africa (85.1 vs. 60.5%, P < 0.001). The median time since HIV diagnosis was 6 years (IQR: 2-9) in Burkina Faso and 4 years (IQR: 2-7) in South Africa.
Among 161 CIN2þ cases detected in the HARP study at baseline, cervical samples were unavailable for nine participants and EPB41L3 methylation was performed for 152 women with CIN2þ (CIN2: Burkina Faso: 17; In both countries, women taking ART were more likely to have 'high' methylation compared with ART-naïve women, but following adjustment, this association remained significant among women taking ART for prolonged duration in South Africa only (ART >2 years vs. ART-naïve: 54.4 vs. 35.6%; aOR 2.40, 95% CI 1.23-4.69).
Performance of EPB41L3 DNA methylation for detection of prevalent cervical intraepithelial neoplasia grade 2, or greater The ROC curve analysis for detection of prevalent CIN2þ relative to CIN1 or less generated an AUC of 0.77 (95% CI 0.65-0.89) in Burkina Faso (Fig. 3a) and 0.68 (95% CI 0.62-0.74) in South Africa (Fig. 3b) . The current cervical cancer screening method in Burkina Faso is VIA/VILI, which had a sensitivity of 60.7% and specificity of 69.7% for CIN2þ detection in Burkina Faso (Fig. 3a) . When setting the sensitivity of the EPB41L3 assay at 60.7%, there was a significant difference in the specificity between the tests (VIA/VILI: 69.7% vs. EPB41L3: 86.4%; McNemar's P ¼ 0.0116).
The current cervical cancer screening method in South Africa is cytology with cut-off of low-grade squamous intraepithelial lesions and greater (LSILþ), which had a sensitivity of 97.5% and specificity of 9.2% for detection of CIN2þ, whereas a cut-off of high-grade SIL and greater (HSILþ) had a sensitivity of 69.7% and specificity of 78.9% (Fig. 3b) . When setting the sensitivity of EPB41L3 similar to that of cytology HSILþ, there was a significant difference in specificity between the tests (HSILþ: 78.9% vs. EPB41L3: 66.2%; McNemar's P ¼ 0.0201), as well as for LSILþ (LSILþ: 9.2% vs. EPB41L3: 97.9%; McNemar's P < 0.001).
The AUC did not vary when considering CIN3þ alone as an outcome measure relative to CIN1 (Burkina Faso: 0.77, 95% CI 0.57-0.97; South Africa: 0.70, 95% CI 0.62-0.78).
Discussion
In this study conducted among African women living with HIV-1, we report that the methylation of the human tumour suppressor gene EPB41L3 increased with increasing severity of CIN at baseline and with progression of CIN lesions over 16 months. Similar to studies among HIV-uninfected women [19] [20] [21] , our data suggest that EPB41L3 methylation may be involved in cervical carcinogenesis and could be useful in identifying women at risk of persistent or progressive high-grade CIN.
Our finding that EPB41L3 methylation levels increased with increasing severity of CIN lesion over time is similar to what has been reported for other host gene markers CADM1, MAL [33] and FAM19A4 [34] in the Netherlands. In our study, women who had not been treated in time before endline and who had persistent CIN3, or CIN2, which progressed to CIN3 had significantly higher baseline EPB41L3 methylation levels compared with women who spontaneously regressed to CIN1or less, and women with nonprogressing CIN2 over 16 months. Although the number of outcomes was small, our results suggest that the EPB41L3 methylation assay may be useful in distinguishing women with CIN2þ that progress from those that regress. Given that over half of untreated women in this study with CIN2/3 at baseline had spontaneous regression to CIN1 over 16 months, such a diagnostic tool would be useful to reduce overreferral with unnecessary colposcopies and overtreatment, which are problematic in limited resources settings.
We found higher levels of EPB41L3 methylation among women with low CD4 þ count (200 cells/ml) compared with women with high CD4 þ count (>350 cells/ml). It is unclear from the literature whether CD4 þ T lymphocytes are directly involved in regulating tumour suppressor genes such as EPB41L3, but CD4 þ T lymphocytes can regulate tumour cells indirectly through the action of cytokines [35] [36] [37] . The inverse correlation of methylation levels with CD4 þ cell count may also reflect the association of high-risk HPV with CD4 þ cell count, as Two women in South Africa denied being on ART at enrolment despite undetectable HIV-1 PVL and given the uncertainty of their status, these women were excluded from HIV-related factors analyses; adjusted odds ratio (aOR).
b
Adjusted for high-risk HPV, CIN status, age and CD4 þ count in both countries, in addition to Candida albicans in Burkina Faso. CD4 þ cell count has been shown to a strong predictor of high-risk HPV prevalence and persistence [5, 6, [38] [39] [40] . HPV oncogenes E6 and E7 can activate DNA methyltransferases, which are responsible for initiating and maintaining tumour suppressor gene methylation and are overexpressed in several cancers [41] . Although the association of CD4 þ cell count with EPB41L3 methylation was independent of high-risk HPV status, unmeasured high-risk HPV particularly in integrated form (E6/E7 integrated in host DNA) cannot be ruled out.
Chronic inflammation as a result of persistent or recurrent genital infections caused by Trichomonas vaginalis, Herpes simplex virus-2 (HSV-2) and bacterial vaginosis, also known to be linked to low CD4 þ cell counts and which were prevalent in this population, can promote the initiation or progression of high-grade cervical lesions [6] . Elevated levels of nitric oxide associated with Trichomonas vaginalis, HSV-2 and bacterial vaginosis may result in DNA damage, silencing of tumour suppressor genes and cell transformation [42, 43] .
Higher methylation of EPB41L3 was found among ART users compared with ART-naïve women in this study and this was independent of CD4 þ cell count, high-risk HPV and CIN status. The mechanisms behind this finding are unclear. In the HARP study, women on prolonged duration ART (>2 years) in South Africa had higher median CD4
þ cell count and correspondingly lower CIN2þ prevalence at baseline compared with ART-naïve women, or women on short-duration ART (2 years) [6] . It is possible that women on ART show a more advanced ageing process than those not on ART, especially if they have been living longer with HIV, as has been shown among other HIV-infected populations [44, 45] . In this study, the median time since HIV diagnosis was 5 years (IQR: 3-8) among women taking ART and 2 years (IQR: 1-4) among the ART-naïve women. Alternatively, the effects may be because of ART genetoxicity and the long-term effects of ART drugs. Animal studies have shown that antiretroviral nucleoside analogue drugs, such as zidovudine are incorporated into host DNA, where it causes mutations of genes associated with gene expression, cell cycle arrest and chromosomal aberrations [46] . Others have shown that zidovudine, or azidothymidine (AZT) can induce site-specific hypermethylation [47] .
In Burkina Faso, EPB41L3 methylation values increased across all grades of CIN, and the EPB41L3 methylation assay had a sensitivity and specificity comparable with the studies conducted among HIV-negative women [19, 21, 24] . The performance of the EPB41L3 methylation assay appears slightly better than the current cervical cancer screening method of VIA/VILI in Burkina Faso. In South Africa, the EPB41L3 methylation assay had lower specificity compared with cytology HSILþ, but was more specific than cytology LSILþ, which is used as a cut-off for colposcopy referral according to national guidelines. These findings suggest that EPB41L3 could be comparable, or not far from the performance of the current morphological screening method, and its performance could be enhanced by the combination of other existing human gene markers and/or high-risk HPV and as a triage test, as shown by others [19, 20] .
The study was constrained by its small sample size and its post hoc case-control design nested into the HARP parent study, although we attempted to match by age and to have at least one control for each case, particularly in Burkina Faso. Although 94% of prevalent cases and 96% of incident CIN2þ cases from the parent HARP study were included, only a proportion of the controls [Burkina Faso: 66/583 (11%), and in South Africa: 144/494 (29%)] were sampled. Therefore, the data might not be entirely generalizable to all women with CIN1 or less in the HARP cohort. Other studies have restricted measurement of DNA methylation markers to high-risk HPV positive women to evaluate their performance as triage tests. In this study, the EPB41L3 DNA methylation assay was performed irrespective of high-risk HPV DNA status to describe the full range of epidemiological associations. The availability of a histological verification at both baseline and endline may have introduced a bias towards positive methylation (even in the absence of true disease) as women needed to have evidence of some abnormality in order to have been biopsied. This may have reduced the chances of increased discriminatory power expected when comparing women with disease to women with a total absence of abnormalities. There was a higher proportion of participants in South Africa with zero percentage methylation for EPB41L3 compared with women in Burkina Faso, which may be attributed to the higher proportion of ART users in Burkina Faso, given their higher median EPB41L3 methylation and there may be epigenetic differences between the two populations linked to different environmental exposures, which can modify the effects of DNA methylation [48, 49] .
Despite these limitations, the study had several strengths, including its longitudinal design, the availability of a rigorously validated histological endpoint for the majority of women, thereby minimizing disease ascertainment bias, and the availability of methylation data at both time points. HARP is one of a few studies investigating DNA methylation of human genes and association with CIN2þ among WLHIV [17, 18] and the only one to study EPB41L3.
In conclusion, methylation of human gene EPB41L3 DNA is elevated in CIN2þ cases among African WLHIV and is higher among women with low CD4 þ cell count. DNA methylation assays show promise as an earlier indicator of precancer and cervical lesion progression in high-risk populations, such as WLHIV, alongside existing screening tools. Given that DNA methylation markers in combination panels generate higher sensitivity and specificity compared with individual genes on their own, multiplex DNA methylation assays including a combination of human genes may have a potential as primary screening of CIN2þ among WLHIV.
